Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%Martin Reck, Julie R. Brahmer, Ali Tafreshi et al.|Journal of Clinical Oncology|2021Cited by 1.1k
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Rolf A. Stahel, Urania Dafni et al.|The Lancet Respiratory Medicine|2017Cited by 184
LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%Julie R. Brahmer, Martin Reck, Delvys Rodríguez‐Abreu et al.|Annals of Oncology|2020Cited by 96
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung TrialSolange Peters, Egbert F. Smit, Rolf A. Stahel et al.|Journal of Thoracic Oncology|2016Cited by 22